Targeted therapies, including the mammalian target of rapamycin (mTOR) inhibitors and anti-angiogenesis tyrosine kinase inhibitors (TKIs), a mainstay of treatment in ccRCC, have shown a variable efficacy, depending on the nccRCC subtype. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.